ANGPTL3 and Hypercholesterolemia: Results of ARO-ANG3 in hypercholesterolemia patients on a stable lipid-lowing regimen showed ANGPTL3 levels dropped by 79–88% on average, and mean maximum reductions in LDL-C was up to 42% (Arrowhead Reports Interim Clinical Data on Cardiometabolic Candidates Aro-Apoc3 and Aro-Ang3, 2020).